Acta Neurologica Belgica

, Volume 112, Issue 3, pp 275–280 | Cite as

Evaluation of serum oxidant/antioxidant balance in multiple sclerosis

  • Abdullah Acar
  • M. Ugur Cevik
  • Osman Evliyaoglu
  • Ertugrul Uzar
  • Yusuf Tamam
  • Adalet Arıkanoglu
  • Yavuz Yucel
  • Sefer Varol
  • Hakan Onder
  • Nebahat Taşdemir
Original Article


The total oxidative status (TOS)/total anti-oxidative status (TAS) ratio can provide information on an individual’s absolute oxidative stress index (OSI). We investigated the alterations in the oxidant–antioxidant balance by measuring the oxidant parameters OSI, TOS, and malondialdehyde (MDA) together with the antioxidant parameters such as TAS, and superoxide dismutase (SOD) in patients with relapsing remitting multiple sclerosis (MS). To our knowledge, this is the first study to evaluate OSI in patients with relapsing remitting MS. 35 ambulatory patients with relapsing–remitting MS (35.8 ± 8.7 years) and 32 age- and activity-matched healthy control subjects (35.1 ± 3.7 years) that participated in the study. Serum TAS and TOS levels were determined using new automated methods. MS patients had higher concentrations of MDA (151.5 ± 51.1 vs. 111.3 ± 27.4 nmol/g protein, respectively; p < 0.001), TOS (148.1 ± 162.5 vs. 48.3 ± 46.4 mmol H2O2 Equiv./g protein, respectively; p = 0.002), OSI (21124 ± 32543 vs. 5294 ± 5562, respectively; p = 0.008), and SOD (4.5 ± 0.7 vs. 3.4 ± 0.6 U/L, respectively; p < 0.001) compared with healthy controls. On the other hand, MS patients had lower concentrations of NO (12.3 ± 6.9 vs. 17.4 ± 2.5 μmol/g protein, respectively; p < 0.001) and TAS (0.82 ± 0.27 vs. 0.26 ± 0.15, respectively; p = 0.011) compared with healthy controls. In conclusion, these findings indicate that the oxidative stress plays an important role in the pathogenesis of MS.


Multiple sclerosis Pathogenesis Oxidative stress index Total oxidant status Total antioxidant status 



This research was part of a project that was financially supported by Research Foundation of Dicle University, so we are thankful for this support.


  1. 1.
    Furlan R, Rovaris M, Martinelli Boneschi F, Khademi M, Bergami A, Gironi M, Deleidi M, Agosta F, Franciotta D, Scarpini E, Uccelli A, Zaffaroni M, Kurne A, Comi G, Olsson T, Filippi M, Martino G (2005) Immunological patterns identifying disease course and evolution in multiple sclerosis patients. J Neuroimmunol 165:192–200PubMedCrossRefGoogle Scholar
  2. 2.
    Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H (2011) Oxidative damage in multiple sclerosis lesions. Brain 134:1914–1924PubMedCrossRefGoogle Scholar
  3. 3.
    Miller E, Mrowicka M, Malinowska K, Mrowicki J, Saluk-Juszczak J, Kędziora J (2011) Effects of whole-body cryotherapy on a total antioxidative status and activities of antioxidative enzymes in blood of depressive multiple sclerosis patients. World J Biol Psychiatry 12:223–227PubMedCrossRefGoogle Scholar
  4. 4.
    Lutskii MA, Esaulenko IE (2007) Oxidant stress in the pathogenesis of multiple sclerosis. Neurosci Behav Physiol 37:209–213PubMedCrossRefGoogle Scholar
  5. 5.
    Ferretti G, Bacchetti T, Principi F, Di Ludovico F, Viti B, Angeleri VA, Danni M, Provinciali L (2005) Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler 11:677–682PubMedCrossRefGoogle Scholar
  6. 6.
    Uzar E, Koyuncuoglu HR, Uz E, Yilmaz HR, Kutluhan S, Kilbas S, Gultekin F (2006) The activities of antioxidant enzymes and the level of malondialdehyde in cerebellum of rats subjected to methotrexate: protective effect of caffeic acid phenethyl ester. Mol Cell Biochem 291:63–68PubMedCrossRefGoogle Scholar
  7. 7.
    Erel O (2005) A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38:1103–1111PubMedCrossRefGoogle Scholar
  8. 8.
    Erel O (2004) A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37:277–285PubMedCrossRefGoogle Scholar
  9. 9.
    Alp R, Selek S, Alp SI, Taşkin A, Koçyiğit A (2010) Oxidative and antioxidative balance in patients of migraine. Eur Rev Med Pharmacol Sci 14:877–882PubMedGoogle Scholar
  10. 10.
    Lowry OH, Rosebrough NJ, Farr AL, Randal RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  11. 11.
    Fridovich I (1974) Superoxide dismutase. Adv Enzymol Relat Areas Mol Biol 41:35–97PubMedGoogle Scholar
  12. 12.
    Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358PubMedCrossRefGoogle Scholar
  13. 13.
    Cortas NK, Wakid NW (1990) Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 36:1440–1443PubMedGoogle Scholar
  14. 14.
    Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B (1993) Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 121:257–262PubMedGoogle Scholar
  15. 15.
    Schreibelt G, van Horssen J, van Rossum S, Dijkstra CD, Drukarch B, de Vries HE (2007) Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev 56:322–330PubMedCrossRefGoogle Scholar
  16. 16.
    Mirshafiey A, Mohsenzadegan M (2009) Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 31:13–29PubMedCrossRefGoogle Scholar
  17. 17.
    Besler HT, Comoğlu S (2003) Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 6:189–196PubMedCrossRefGoogle Scholar
  18. 18.
    Koch M, Mostert J, Arutjunyan AV, Stepanov M, Teelken A, Heersema D, De Keyser J (2007) Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 14:529–533PubMedCrossRefGoogle Scholar
  19. 19.
    Besler HT, Comoğlu S, Okçu Z (2002) Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis. Nutr Neurosci 5:215–220PubMedCrossRefGoogle Scholar
  20. 20.
    Ortiz GG, Macías-Islas MA, Pacheco-Moisés FP, Cruz-Ramos JA, Sustersik S, Barba EA, Aguayo A (2009) Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers 26:35–39PubMedGoogle Scholar
  21. 21.
    Koch M, Ramsaransing GS, Arutjunyan AV, Stepanov M, Teelken A, Heersema DJ, De Keyser J (2006) Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J Neurol 253:483–487PubMedCrossRefGoogle Scholar
  22. 22.
    Mitosek-Szewczyk K, Gordon-Krajcer W, Walendzik P, Stelmasiak Z (2010) Free radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy. Folia Neuropathol 48:116–122PubMedGoogle Scholar
  23. 23.
    Kurban S, Akpınar Z, Mehmetoğlu I (2010) Investigation of serum paraoxonase and arylesterase activities and oxidative stress in patients with multiple sclerosis. Genel Tıp Derg (Turkish) 20:13–18Google Scholar
  24. 24.
    Guerrero AL, Gutiérrez F, Iglesias F, Martín-Polo J, Merino S, Martín-Serradilla JI, Laherrán E, Tejero MA (2011) Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci 32:347–350PubMedCrossRefGoogle Scholar
  25. 25.
    Syburra C, Passi S (1999) Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh 71:112–115PubMedGoogle Scholar
  26. 26.
    Choi IY, Lee SP, Denney DR, Lynch SG (2011) Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T. Mult Scler 17:289–296PubMedCrossRefGoogle Scholar
  27. 27.
    Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F (2010) Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain–Barre syndrome and multiple sclerosis patients. Int J Neurosci 120:301–304PubMedCrossRefGoogle Scholar
  28. 28.
    Johnson F, Giulivi C (2005) Superoxide dismutases and their impact upon human health. Mol Aspects Med 26:340–352PubMedCrossRefGoogle Scholar
  29. 29.
    Singh BK, Kumar A, Ahmad I, Kumar V, Patel DK, Jain SK, Singh C (2011) Oxidative stress in zinc-induced dopaminergic neurodegeneration: implications of superoxide dismutase and heme oxygenase-1. Free Radic Res 45:1207–1222PubMedCrossRefGoogle Scholar
  30. 30.
    Tajouri L, Mellick AS, Ashton KJ, Tannenberg AE, Nagra RM, Tourtellotte WW, Griffiths LR (2003) Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res 119:170–183PubMedCrossRefGoogle Scholar
  31. 31.
    Koch M, Mostert J, Arutjunyan A, Stepanov M, Teelken A, Heersema D, De Keyser J (2008) Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosis. Mult Scler 14:159–165PubMedCrossRefGoogle Scholar
  32. 32.
    Yamashita T, Ando Y, Obayashi K, Uchino M, Ando M (1997) Changes in nitrite and nitrate (NO2−/NO3−) levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci 153:32–34PubMedCrossRefGoogle Scholar
  33. 33.
    Brundin L, Morcos E, Olsson T, Wiklund NP, Andersson M (1999) Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker. Eur J Neurol 6:585–590PubMedCrossRefGoogle Scholar
  34. 34.
    de Bustos F, Navarro JA, de Andrés C, Molina JA, Jiménez-Jiménez FJ, Ortí-Pareja M, Gasalla T, Tallón-Barranco A, Martínez-Salio A, Arenas J (1999) Cerebrospinal fluid nitrate levels in patients with multiple sclerosis. Eur Neurol 41:44–47PubMedCrossRefGoogle Scholar
  35. 35.
    Ikeda M, Sato I, Matsunaga T, Takahashi M, Yuasa T, Murota S (1995) Cyclic guanosine monophosphate (cGMP), nitrite and nitrate in the cerebrospinal fluid in meningitis, multiple sclerosis and Guillain-Barré syndrome. Int Med 34:734–737CrossRefGoogle Scholar

Copyright information

© Belgian Neurological Society 2012

Authors and Affiliations

  • Abdullah Acar
    • 1
  • M. Ugur Cevik
    • 1
  • Osman Evliyaoglu
    • 2
  • Ertugrul Uzar
    • 1
  • Yusuf Tamam
    • 1
  • Adalet Arıkanoglu
    • 1
  • Yavuz Yucel
    • 1
  • Sefer Varol
    • 1
  • Hakan Onder
    • 3
  • Nebahat Taşdemir
    • 1
  1. 1.Department of Neurology, Faculty of Medicine, School of MedicineDicle UniversityDiyarbakırTurkey
  2. 2.Department of Biochemistry, Faculty of MedicineDicle UniversityDiyarbakırTurkey
  3. 3.Department of Radiology, Faculty of MedicineDicle UniversityDiyarbakırTurkey

Personalised recommendations